1. Able and willing to provide a written informed consent;

2. Male or female subjects, 18-65 years of age at the time of signing informed consent;

3. At screening visit, 28.0 ≤BMI≤ 40.0 kg/m2;

4. Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months;

5. Non-pregnant or lactating women. Fertile male and female (including partners) agree to use highly effective contraceptive methods.

1. Uncontrollable hypertension;

2. Presence of - clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;

3. PHQ-9 score ≥15;

4. Medical history or illness that affects body weight;

5. History of diabetes;

6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;

7. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening;

8. Any organ-system malignancies developed within 5 years;

9. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;

10. History of alcohol and/or substance abuse or drug abuse;

11. Use of any medication or treatment that may have caused significant weight change within 3 months;

12. History of bariatric surgery;

13. Known or suspected hypersensitivity to trial product(s) or related products;

14. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;

15. Surgery is planned during the trial;

16. Mentally incapacitated or speech-impaired;

17. Acute or chronic hepatitis;

18. The investigators determined that other conditions were inappropriate for participation in this clinical trial.